Christopher J. Scoggins serves as Executive Vice President of Diabetes Care at Abbott Laboratories, overseeing the global strategy, operations, and innovation for one of the company's fastest-growing franchises. In this role, he leads a team dedicated to advancing continuous glucose monitoring (CGM) technologies, such as the FreeStyle Libre portfolio, which has transformed diabetes management for millions worldwide by providing real-time insights and reducing the burden of fingerstick testing. Scoggins drives cross-functional initiatives to expand market access, enhance product integration with digital health platforms, and accelerate R&D pipelines aimed at simplifying therapy for people with diabetes. With more than 25 years in the medical technology sector, Scoggins brings a proven track record of commercial success and strategic leadership. Prior to Abbott, he was Senior Vice President of Global Diabetes at Medtronic, where he spearheaded the launch of the MiniMed 670G hybrid closed-loop system, achieving over $2 billion in annual revenue and establishing market leadership in automated insulin delivery. Earlier roles included executive positions at Dexcom and Johnson & Johnson, where he honed expertise in regulatory approvals, international expansion, and payer negotiations, consistently delivering double-digit growth in competitive markets. Scoggins holds a Bachelor of Science in Biomedical Engineering from the Georgia Institute of Technology and an MBA from the Wharton School of the University of Pennsylvania. His achievements have earned him recognition, including MedTech Executive of the Year and induction into the Diabetes Technology Hall of Fame. At Abbott, he continues to champion patient-centric innovation, forging partnerships with healthcare systems and leveraging AI to personalize diabetes care, positioning the company for sustained leadership in a rapidly evolving therapeutic landscape.